Charalampos Papachristou

Charalampos Papachristou


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Bioactive Materials
Verified
Journal Article
Open access
RYRachel E. Young
Rachel E. Young
KNKatherine M. Nelson
Katherine M. Nelson
SHSamuel I. Hofbauer
Samuel I. Hofbauer
TVTara Vijayakumar
Tara Vijayakumar
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
RRRachel S. Riley
Rachel S. Riley
Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA stability, circulation time, cellular uptake, and preferential delivery to specific tissues compared to mRNA with no carrier platform. However, LNPs are only in the beginning stages of development for safe and effective mRNA delivery to the placenta to treat placental dysfunction. Here, we develop LNPs that enable high levels of mRNA delivery to trophoblasts in vitro and to the placenta in vivo with no toxicity. We conducted a Design of Experiments to explore how LNP composition, including the type and molar ratio of each lipid component, drives trophoblast and placental delivery. Our data revealed that utilizing C12-200 as the ionizable lipid and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) as the phospholipid in the LNP design yields high transfection efficiency in vitro. Analysis of lipid molar composition as a design parameter in LNPs displayed a strong correlation between apparent pKa and poly (ethylene) glycol (PEG) content, as a reduction in PEG molar amount increases apparent pKa. Further, we present one LNP platform that exhibits the highest delivery of placental growth factor mRNA to the placenta in pregnant mice, resulting in synthesis and secretion of a potentially therapeutic protein. Lastly, our high-performing LNPs have no toxicity to both the pregnant mice and fetuses. Our results demonstrate the feasibility of LNPs as a platform for mRNA delivery to the placenta, and our top LNP formulations may provide a therapeutic platform to treat diseases that originate from placental dysfunction during pregnancy.

1 October 2011 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CMCaroline A. Motika
Caroline A. Motika
CPCharalampos Papachristou
Charalampos Papachristou
MAMark Abney
Mark Abney
LLLucille A. Lester
Lucille A. Lester
COCarole Ober
Carole Ober

22 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
RYRachel E. Young
Rachel E. Young
KNKatherine M. Nelson
Katherine M. Nelson
SHSamuel I. Hofbauer
Samuel I. Hofbauer
TVTara Vijayakumar
Tara Vijayakumar
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
RRRachel S. Riley
Rachel S. Riley
Ionizable lipid nanoparticles (LNPs) have gained attention as mRNA delivery platforms for vaccination against COVID-19 and for protein replacement therapies. LNPs enhance mRNA stability, circulation time, cellular uptake, and preferential delivery to specific tissues compared to mRNA with no carrier platform. However, LNPs have yet to be developed for safe and effective mRNA delivery to the placenta as a method to treat placental dysfunction. Here, we develop LNPs that enable high levels of mRNA delivery to trophoblasts in vitro and to the placenta in vivo with no toxicity. We conducted a Design of Experiments to explore how LNP composition, including the type and molar ratio of each lipid component, drives trophoblast and placental delivery. Our data revealed that a specific combination of ionizable lipid and phospholipid in the LNP design yields high transfection efficiency in vitro . Further, we present one LNP platform that exhibits highest delivery of placental growth factor mRNA to the placenta in pregnant mice, which demonstrates induced protein synthesis and secretion of a therapeutic protein. Lastly, our high-performing LNPs have no toxicity to both the pregnant mice and fetuses. Our results demonstrate the feasibility of LNPs as a platform for mRNA delivery to the placenta. Our top LNPs may provide a therapeutic platform to treat diseases that originate from placental dysfunction during pregnancy.

4 April 2011 in Genetic Epidemiology
Verified
Journal Article
Closed access
PDF file
CPCharalampos Papachristou
Charalampos Papachristou
COCarole Ober
Carole Ober
MAMark Abney
Mark Abney

31 December 2003 in BMC Genomic Data
Verified
Journal Article
Open access
PDF file
SBSwati Biswas
Swati Biswas
CPCharalampos Papachristou
Charalampos Papachristou
MIMark E Irwin
Mark E Irwin
SLShili Lin
Shili Lin
The goal of this study is to evaluate, compare, and contrast several standard and new linkage analysis methods. First, we compare a recently proposed confidence set approach with MAPMAKER/SIBS. Then, we evaluate a new Bayesian approach that accounts for heterogeneity. Finally, the newly developed software SIMPLE is compared with GENEHUNTER. We apply these methods to several replicates of the Genetic Analysis Workshop 13 simulated data to assess their ability to detect the high blood pressure genes on chromosome 21, whose positions were known to us prior to the analyses. In contrast to the standard methods, most of the new approaches are able to identify at least one of the disease genes in all the replicates considered.

17 June 2014 in BMC Proceedings
Verified
Journal Article
Open access
PDF file
SBSwati Biswas
Swati Biswas
CPCharalampos Papachristou
Charalampos Papachristou
It has been hypothesized that rare variants may hold the key to unraveling the genetic transmission mechanism of many common complex traits. Currently, there is a dearth of statistical methods that are powerful enough to detect association with rare haplotypes. One of the recently proposed methods is logistic Bayesian LASSO for case-control data. By penalizing the regression coefficients through appropriate priors, logistic Bayesian LASSO weeds out the unassociated haplotypes, making it possible for the associated rare haplotypes to be detected with higher powers. We used the Genetic Analysis Workshop 18 simulated data to evaluate the behavior of logistic Bayesian LASSO in terms of its power and type I error under a complex disease model. We obtained knowledge of the simulation model, including the locations of the functional variants, and we chose to focus on two genomic regions in the MAP4 gene on chromosome 3. The sample size was 142 individuals and there were 200 replicates.